Abstract:The proliferative endothelial and smooth muscle cell phenotype, inflammation, and pulmonary vascular remodeling are prominent features of pulmonary arterial hypertension (PAH). Mutations in bone morphogenetic protein type 2 receptor (BMPR2) have been identified as the most common genetic cause of PAH and females with BMPR2 mutations are 2.5 times as likely to develop heritable forms of PAH than males. Higher levels of estrogen have also been observed in males with PAH, implicating sex hormones in PAH pathogenesis. Recently, the estrogen metabolite 16α-OHE1 (hydroxyestrone) was implicated in the regulation of miR29, a microRNA involved in modulating energy metabolism. In females, decreased miR96 enhances serotonin's effect by upregulating the 5-hydroxytryptamine 1B (5HT1B) receptor. Because PAH is characterized as a quasi-malignant disease, likely due to BMPR2 loss of function, altered signaling pathways that sustain this cancer-like phenotype are being explored. Extracellular signal-regulated kinases 1 and 2 and p38 mitogen-activated protein kinases (MAPKs) play a critical role in proliferation and cell motility, and dysregulated MAPK signaling is observed in various experimental models of PAH. Wnt signaling pathways preserve pulmonary vascular homeostasis, and dysregulation of this pathway could contribute to limited vascular regeneration in response to injury. In this review, we take a closer look at sex, sex hormones, and the interplay between sex hormones and microRNA regulation. We also focus on MAPK and Wnt signaling pathways in the emergence of a proproliferative, antiapoptotic endothelial phenotype, which then orchestrates an angioproliferative process of vascular remodeling, with the hope of developing novel therapies that could reverse the phenotype.Keywords: vascular remodeling, sex hormones, microRNA, mitogen-activated protein kinase, Wnt. Pulmonary arterial hypertension (PAH) is a rare disorder characterized by endothelial cell proliferation, pulmonary vascular remodeling, pruning of distal vessels, and increased pulmonary resistance, culminating in right heart failure and death.1 Although the initial mechanisms responsible for the development of idiopathic PAH (IPAH) and other forms of PAH remain unknown, loss of normal bone morphogenetic protein type 2 receptor (BMPR2) function has been implicated in the formation of plexogenic lesions. 2 These plexogenic lesions are believed to be a result of dysregulated angiogenesis, with proliferation of endothelial cells, vascular smooth muscle cells, myofibroblasts, and inflammatory cells in and around occluded pulmonary arteries.3 PAH develops more predominately in women than in men; survival is, however, poorer in men. These sex differences are incompletely understood. Female predominance suggests that sex hormones contributes to pulmonary vascular remodeling, in part through the ability of estrogen (E2) to reduce BMPR2 expression. 4 However, in some experimental models of PAH (monocrotaline and chronic hypoxia), E2 appears to protect against PAH,...